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Introduction
Benign and malignant tumors of the breast predominantly
arise from glandular epithelium. In some cases, however,
glandular epithelium differentiates into nonglandular
mesenchymal tissue, a process termed metaplasia (Brenner
et al., 1998). Pathogenesis of such diverse elements has been
the subject of much controversy.
Metaplastic changes in the breast include squamous cell,
spindle cell, and heterologous mesenchymal growth and
occur in fewer than 5% of breast carcinomas (Wargotz and
Norris, 1989a; 1989b; 1990a; 1990b; Wargotz  et al., 1989;
Pitts et al., 1991). Carcinosarcomas, a subgroup of
metaplastic carcinomas, are the rarest primary malignancies
of the breast, found in < 0.1% of cases (Feder et al., 1999).
Wargotz  and Norris (1989a; 1989b and 1990a) and Wargotz
et al (1989) categorized metaplastic carcinoma breast (MCB)
into four variants which included matrix-producing
carcinoma, spindle cell carcinoma, squamous cell carcinoma,
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Abstract
Metaplastic carcinoma breast is categorized as a rare heterogenous neoplasm generally characterized by a mixture
of adenocarcinoma with dominant areas of spindle cell, squamous and/or other mesenchymal differentiation. To
determine the epidemio-demographic and histopathologic characteristics of this rare entity a retrospective study
was conducted to review all cases at the Aga Khan University Hospital (AKUH) Karachi, received during 1st January
2000 to 31st August 2005. Twenty-four patients were identified with a mean age at diagnosis of 46.4 (±SD 3.8) years,
and an age range of 28-68 years. The mean tumor size was 7.9 cm, range 2.0–17.0 cms (±SD 4.77). The specimens
were mostly obtained by modified radical mastectomy(54.2%) followed by biopsy (29.2%), lumpectomy (8.3%),
and total mastectomy (4.2%). Skin ulceration was found in 37.5% cases. Component sub-categorization showed 13
(54.2%) cases of infiltrating ductal carcinoma with squamous metaplasia, followed by 2 (8.3 %) cases with heterologous
elements, 4 (16.7%) cases with spindle cell component, 2 cases of matrix producing carcinoma and one case of
squamous cell carcinoma. The malignancy was high grade, modified Bloom Richardson’s grade III (54.2 %) and
grade II (12.5%). Such grading was not applicable to 4 cases of spindle cell component and 1 case with extensive
chondroid areas. Twelve patients had information available on the nodal status. Five (41.6%)  were node-negative,
four (33.33%) had 1-3 lymph node involvement positive, and three (12.5%) had more than 3 lymph nodes positive.
The median 3 year Event Free Survival (EFS) was 10% and overall survival was 30%. MCB is an aggressive disease
with a poor prognosis. This aspect appears bleaker in our population either due to the biological characteristic of the
malignancy in a high risk group or the lack of availability and accessibility of health coverage, resulting in a delayed
presentation. MCB is an uncommon breast malignancy and due to the lack of sufficiently large studies there is
limited knowledge as to the pathogenesis, progress, best treatment protocols and prognosis. Collaborative studies
are therefore recommended to allow for better understanding of this intriguing neoplasm.
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and carcinosarcoma. Earlier, Oberman in 1987 had suggested
that all such tumors be categorized as metaplastic carcinoma
of the breast (MCB), de-emphasizing whether the
metaplastic component is of mesenchymal or epithelial
origin. Subsequently, after the advent of
immunohistochemistry, it was generally accepted that
metaplasia of the epithelial elements of a carcinoma gives
MCB a pseudosarcomatous appearance. Hence the name is
given to malignant breast neoplasms which show cytokeratin
positivity in both epithelial and mesenchymal elements
(Saxena et al., 2004). At present, MCB is considered a rare
heterogeneous group of neoplasms ranging from tumors with
a predominant component of overt carcinoma and focal
mesenchymal differentiation to keratin-positive tumors with
pure sarcomatoid morphology (Davis et al., 2005).
Morphologically, the malignancy is characterized by an
intimate admixture of epithelial and mesenchymal elements
in variable combinations. MCB encompasses epithelial only
carcinoma (high grade adenosquamous carcinoma or pure
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squamous cell carcinoma), biphasic epithelial and
sarcomatoid carcinoma and monophasic spindle cell
carcinoma (Tse, 2006). Largely, the predominant
morphological pattern is adenocarcinoma with dominant
areas of spindle cell, squamous and/or mesenchymal
differentiation. Rarely osseous differentiation is also
observed (Pollock et al., 2006).
MCB often manifests as a rapidly growing, palpable
mass. The average age at presentation is approximately 55
years and the median size of malignancy at presentation is
usually 3-4 cm. MCB is mostly negative for hormone
receptors (HR) i.e. estrogen and progesterone receptors (ER;
PR) and HER2/neu oncoprotein. Nodal metastasis is
relatively uncommon. An aggressive form of breast cancer,
it is associated with poor outcome, high incidence of local
recurrence and pulmonary metastases. Tumor size has an
important impact on outcome and prognosis (Al Sayed et
al, 2006). Advanced stage and lymph node involvement are
associated with a more aggressive course. The five year
survival is less than that of infiltrating ductal carcinoma.
Because MCB comprises a heterogeneous group of tumors,
it has been difficult to reliably predict its biologic potential
(Carter et al., 2006).
Matrix-producing carcinoma of breast displaying
myoepithelial phenotype is a very aggressive lesion and
differs from conventional myoepithelial carcinoma and from
heterologous metaplastic carcinoma, where the matrix
emanate from undifferentiated sarcomatous tissue. The
spectrum of differential diagnosis includes benign mixed
tumor, phylloides tumor, primary breast sarcoma and colloid
carcinoma (Kinkor et al., 2004).
Considering MCB in the differential diagnosis of breast
masses is important for the purpose of treatment and
prognosis (Brenner et al., 1998; Wargotz et al., 1989). On
mammography it can mimic benign lesions as it has a
predominantly circumscribed, non-calcified appearance. The
margins are more likely to be circumscribed, when the tumor
is composed solely of spindle cells (Patterson, 1997). The
distinction between MCB and sarcoma is preoperatively
important because the surgical treatment, chemotherapy
regimens and metastatic pathways are different. Typically,
axillary lymph node involvement is rare in breast sarcoma
even when the disease is diffusely disseminated, whereas
lymph node metastases are reported in 25-30% of cases with
metaplastic carcinomas (Brenner et al., 1998; Wargotz et
al., 1989).
Materials and Methods
This retrospective descriptive study was carried out at
the Aga Khan University Hospital (AKUH) pathology
department. All consecutive cases of MCB (ICD-O3
categories M-8575) diagnosed during the last decade (1st
January 2000 to 31st August 2005) in the section of
histopathology were reviewed for the study. This included
cases primarily diagnosed at AKUH pathology department
and also second opinion slides. Patients were identified
through the AKUH pathology archived data using SNOMED
code.
Originally all specimens had been fixed in 10% buffered
formalin, grossed and representative sections taken
according to established protocols. The sections had been
routinely processed under standardized conditions for
paraffin embedding. The sections had been cut and stained
with hematoxylin and eosin (H&E) using a standard format
incorporating all the relevant parameters. The cases had been
evaluated and diagnosed after consensus interpretation of
slides. For the present study, archived microscopic slides
were reviewed by a pathologist who was a breast pathology
specialist. Immunohistochemical analysis was performed in
9 cases by employing the envision technique. The mixed
cell origin of MCB was corroborated by histopathologic
staining for mesenchymal cells (vimentin), epithelial cells
(cytokeratin), and myoepithelial cells (S-100 protein, actin,
and high-molecular-weight cytokeratin).
Clinical information, pathologic size, morphological
findings, and lymph node status were obtained from the
surgical pathology reports. Variables recorded were the
hospital patient-number, date of incidence, name, age, sex,
address, topography, morphology, grading and staging. All
morphological and biological types were included; there
were no exclusion criteria within the diagnosis of MCB.
Cases were categorized by the age of the patient,
morphological and biological presentation of the tumor. The
information taken from archived reports was rechecked and
survival status established. The data were analyzed using
SPSS 13.0.
The pathology department of AKUH receives surgical
specimens from AKUH, Karachi and through 84 pathology
laboratory collection points in Pakistan. It covers a large
geographical area, with collection points located in all major
cities like Karachi, Hyderabad, Multan, Lahore, Quetta,
Peshawar, Islamabad, Rawalpindi, Larkana and also many
rural locations. Quality control for diagnostic pathology is
maintained through internal and external quality checks.
External quality assurances for diagnostic pathology are
maintained by the College of American Pathologists (CAP)
surveys. Internal quality assurances are maintained by the
use of histochemical stains, immunohistochemical
techniques. Biological markers are used for malignancies,
which necessitates cellular typing and sub typing. The
departmental consensus committee confirms diagnosis.
Results
Twenty four cases of MCB received over a five year 8
month period were analyzed. All patients were women, with
an age range of 28-68 years. The mean age at diagnosis was
46.4 (±SD 3.8) years and the median age was 49 years. The
presenting complaint was a rapidly growing palpable breast
mass. No patient reported a familial risk factor for breast
cancer.
The surgical specimens were obtained for diagnostic
assessment by modified radical mastectomy (MRM) in 13
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(54.2%) cases, core biopsy in 7 (29.2%), breast conserving
surgery in (BCS), lumpectomy in 2 (8.3%) and total
mastectomy in 1 (4.2%). In the one (4.2%) second opinion
case, the mode of surgery wasnot specified.
On gross examination skin was ulcerated in 9 (37.5%)
cases, normal in 9 (37.5%) and in 6 (25.0%)  skin was neither
available as part of the specimen, nor clinical information
available, so that skin involvement could not be commented
on. The tumor was observed on the left side in 12 (50%)
cases, on the right side in 5 (20.8%) cases. Laterality was
not known in 7 (29.2%) cases. The exact size of the tumor
was available in 16 cases with range of 2-17cms and a  mean
and standard deviation of 7.9 ±SD 4.77.
Component sub-categorization showed 14 (58.4%) cases
of infiltrating ductal carcinoma with squamous metaplasia,
5 (20.8%) with spindle cell components, 2 (8.3 %)  with
heterologous elements, 2 (8.3%) of matrix producing
carcinoma, and one of squamous cell carcinoma (4.2%).
Immunochemistry as a diagnostic tool was essential in 5
cases with spindle cell components, 2 with heterologous
elements and 2 of matrix producing carcinoma. Vimentin
and cytokeratin were positive in all 9 cases, S100 protein
was positive in 2 of the 5 cases in which it was used and
smooth muscle actin was positive in 1 out of the 6 cases in
which it was used.
Modified Bloom Richardson grading was used to grade
16 cases. Thirteen (54.2%) cases were grade III and 3
(12.5%) cases were grade II. Modified Bloom Richardson
grading was not possible in 8 high grade cases, 5 cases of
vimentin positive spindle cell type (see Figure 1a), 2 cases
of matrix producing carcinoma, and one case of squamous
cell carcinoma. Lymph nodes were recovered in 12 of the
13 cases of MRM. In 5 (41.6%) cases lymph node metastasis
was not present. In 4 (33.3%) cases 1-3 lymph nodes were
involved (N1) and in 3 cases (25.0%) more than 3 lymph
nodes were involved (N2).
The tumor margin was positive in 2 (14.2%) of the 14
cases of MRM and total mastectomy. The margin was close,
within or <5 mm in 4 (28.57%) cases and free in 8 (57.1%)
cases. Estrogen receptor studies were available in 10 (41.6
%) cases which were all negative. Progesterone receptor
studies were available in 7 (29.16%) cases and were negative
in 6 (85.7%) cases. The median 3 year event free survival
(EFS) was 10% and overall survival was 30%.
Discussion
    MCBs are regarded as ductal carcinomas that undergo
metaplasia into a nonglandular growth pattern (Brenner et
al., 1998; Wargotz et al., 1989). Due to the rarity of the
disease, published work is limited to mostly single case
reports (Alam et al., 2003; Greenberg et al., 2004) or a few
small series (Al Sayed et al., 2006; Carter et al., 2006; Dave
et al., 2006; Davis et al., 2005; Kuo et al., 2000; Chao et al.,
1999) thus restricting comparisons. The prognostic criteria
used to determine MCB aggressiveness are age of
occurrence, stage of the disease, size of the lesion, lymph
node status, histologic type and grade and the grade of the
mesenchymal component. On the basis of these criteria of
comparison, it is our observation that the MCB in the present
study and largely in Asia is a more aggressive disease.
Most western studies cite an older age group involvement
by MCB, which is reportedly more common in women above
50 years of age (Pitts et al., 1991; Wargotz and Norris, 1989;
1990; Oberman, 1987; Taylor et al., 1994). Carter et al in
2006 reviewed 29 cases of MCB in the United States. The
patients in their series were older then in ours series, with a
median age of 68 years and a range of 40 to 96 years. In
comparison MCB presents in a younger age group in Asians.
In different Asian settings, the median age of presentation
reported was 52.5 years in a series of 8 patients (Kuo et al,
2000), 50.5 years in a series of 14 cases (Chao et al, 1999),
48.0 years in a series of 19 patients (Al Sayed et al, 2006)
and 49.0 years in the present series of 24 patients.
The size of the malignancy at diagnosis is a reflection of
rapid growth and biological behaviour of the tumour, or a
Figure 1. Spindle Cell Metaplastic Carcinoma of the Breast a) H&E, b) Vimentin Staining
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